Memorial Stone County Medical Center Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1440 Central Ave E, Wiggins, MS 39577 Phone: 601-928-6600 Fax: 601-928-6610 |
Wiggins Clinic Family Medicine Medicare: Medicare Enrolled Practice Location: 805 Hall St, Wiggins, MS 39577 Phone: 601-928-4412 Fax: 601-928-4792 |
Wiggins Primary Care Family Medicine Medicare: Medicare Enrolled Practice Location: 975 Hall St, Wiggins, MS 39577 Phone: 601-528-9119 Fax: 601-528-9193 |
Stone County Family Medical Clinic Clinic/Center - Rural Health Medicare: Not Enrolled in Medicare Practice Location: 1434 Central Ave E, Wiggins, MS 39577 Phone: 601-928-6600 Fax: 601-928-6658 |
Poplarville Family Medical Clinic Clinic/Center - Rural Health Medicare: Not Enrolled in Medicare Practice Location: 1434 Central Ave E, Wiggins, MS 39577 Phone: 601-928-6600 Fax: 601-928-6658 |
News Archive
Industrial microbiologists now have a new tool that was designed specifically to help quality control laboratories rapidly screen raw materials, as well as in-process and finished goods, for the presence of microorganisms that can threaten product quality.
How messages sent within stem cells through a specific communication pathway can trigger the cells to specialize and become blood cells in humans, has been discovered by scientists of the McMaster Stem Cell and Cancer Research Institute.
MSNBC's First Read reports that Senate Finance Committee Chairman Max Baucus released a statement earlier today saying that his panel "is still working on a bipartisan bill." According to MSNBC, Baucus said: "Bipartisan progress continues.
A new study published this week in the Journal of Neurosurgery: Pediatrics finds that operative plans for removing Juvenile Pilocytic Astrocytoma, or JPA, tumors in the thalamus of the brain can be augmented with Diffusion Tensor Imaging, or DTI. The sensitivity of DTI imaging allows for the visualization of nerve fiber bundles in the brain.
Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.
› Verified 7 days ago